Citation
Yao, Xueting, et al. "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2020.
Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., & Liu, D. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciaa237
Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9; PubMed PMID: 32150618.
TY - JOUR
T1 - In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AU - Yao,Xueting,
AU - Ye,Fei,
AU - Zhang,Miao,
AU - Cui,Cheng,
AU - Huang,Baoying,
AU - Niu,Peihua,
AU - Liu,Xu,
AU - Zhao,Li,
AU - Dong,Erdan,
AU - Song,Chunli,
AU - Zhan,Siyan,
AU - Lu,Roujian,
AU - Li,Haiyan,
AU - Tan,Wenjie,
AU - Liu,Dongyang,
Y1 - 2020/03/09/
PY - 2020/02/25/received
PY - 2020/3/10/entrez
PY - 2020/3/10/pubmed
PY - 2020/3/10/medline
KW - Chloroquine
KW - Hydroxychloroquine
KW - SARS-CoV-2
JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
JO - Clin. Infect. Dis.
N2 - BACKGROUND: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile. RESULTS: Hydroxychloroquine (EC50=0.72 μM) was found to be more potent than chloroquine (EC50=5.47 μM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.
SN - 1537-6591
UR - https://www.unboundmedicine.com/medline/citation/32150618/In_Vitro_Antiviral_Activity_and_Projection_of_Optimized_Dosing_Design_of_Hydroxychloroquine_for_the_Treatment_of_Severe_Acute_Respiratory_Syndrome_Coronavirus_2_(SARS-CoV-2)
L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciaa237
DB - PRIME
DP - Unbound Medicine
ER -
